Daicel Corporation (DACHF)
| Market Cap | 2.39B +1.6% |
| Revenue (ttm) | 3.65B +2.2% |
| Net Income | 61.03M -76.9% |
| EPS | 0.23 -76.0% |
| Shares Out | n/a |
| PE Ratio | 39.19 |
| Forward PE | n/a |
| Dividend | 0.19 (2.37%) |
| Ex-Dividend Date | Sep 29, 2026 |
| Volume | n/a |
| Open | 8.00 |
| Previous Close | 8.00 |
| Day's Range | 8.00 - 8.00 |
| 52-Week Range | 8.00 - 8.49 |
| Beta | 0.55 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 6, 2026 |
About Daicel
Daicel Corporation engages in the materials, medical/healthcare, smart, safety, and engineering plastics businesses in Japan and internationally. The company offers medical/healthcare products, including BELLOCEA S7, a spherical cellulose acetate particle; FLAVOCELL S-Equol; Urolithin A; polyglycerols; konjac ceramide; excipients for foods; chiral columns and reagents; and Actranza lab, as well as separation and analytical services. It also provides performance films, solvents for electronic materials, cycloaliphatic epoxies, polymers for photo... [Read more]
Financial Performance
In fiscal year 2026, Daicel's revenue was 579.63 billion, a decrease of -1.18% compared to the previous year's 586.53 billion. Earnings were 10.18 billion, a decrease of -79.43%.
Financial numbers in JPY Financial StatementsNews
Daicel Quarterly report: Q1 2027
Daicel has published its Q1 2027 quarterly earnings report on July 31, 2026.
Daicel Slides: Q1 2027
Daicel has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on July 31, 2026.
Daicel Slides: Q4 2026
Daicel has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 11, 2026.
Daicel Quarterly report: Q4 2026
Daicel has published its Q4 2026 quarterly earnings report on May 11, 2026.
Daicel downgraded to Sell from Neutral at Goldman Sachs
Goldman Sachs downgraded Daicel (DACHF) to Sell from Neutral with a price target of 1,480 yen, up from 1,380 yen. The firm sees downside risk to earnings in the company’s…
Daicel Quarterly report: Q3 2026
Daicel has published its Q3 2026 quarterly earnings report on February 4, 2026.
Daicel Slides: Q3 2026
Daicel has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on February 4, 2026.
Daicel downgraded to Neutral from Buy at Goldman Sachs
Goldman Sachs analyst Atsushi Ikeda downgraded Daicel (DACHF) to Neutral from Buy with a price target of 1,380 yen, down from 1,600 yen. Daicel’s Q2 operating profits fell 50% year-over-year…
Daicel Slides: Corporate presentation
Daicel has posted slides in relation to its latest quarterly earnings report, which was published on November 6, 2025.
Daicel Quarterly report: Q2 2026
Daicel has published its Q2 2026 quarterly earnings report on November 5, 2025.
Daicel Slides: Q2 2026
Daicel has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on November 5, 2025.
Daicel downgraded to Equal Weight from Overweight at Morgan Stanley
Morgan Stanley downgraded Daicel (DACHF) to Equal Weight from Overweight with a price target of 1,400 yen, down from 2,300 yen. The firm expects the fiscal year to start with…
Daicel upgraded to Buy from Neutral at Goldman Sachs
Goldman Sachs analyst Atsushi Ikeda upgraded Daicel to Buy from Neutral with a price target of 1,240 yen, up from 1,020 yen. Greater demand for iQOS and other heated tobacco…